Aldeyra Therapeutics NASDAQ:ALDX is reporting this earnings, what to expect.
Aldeyra Therapeutics NASDAQ:ALDX headquartered in Lexington, Massachusetts, United States is reporting their earnings on 05/15/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.37.
According to stock market daily analyst this is Lower then same time previous year. Aldeyra Therapeutics, reported EPS for the same quarter last year was $-0.37.
Overview of Aldeyra Therapeutics NASDAQ:ALDX
Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing, and commercializing products that treat inflammation and inborn errors of metabolism. Aldeyra’s lead product candidate, reproxalap (formerly known as ADX-102), is a small molecule aldehyde sequestering agent in Phase 2b clinical development for the treatment of dry eye disease, and Phase 3 clinical development for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome.
|% Change from 52 Week Low|
|% Change from 52 Week High|